secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001104659-25-068709
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18
----------------------------------------------------------------------

- Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
- Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.
- Shares approved for OTCQB quotation under same symbol BCLI starting July 18.
- CEO states delisting does not alter mission; focus on NurOwn Phase 3b trial under SPA with FDA.
- Company confirms no impact on business operations or ongoing R&D efforts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/tm2521145d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-068709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer